What a $200B blockbuster drug reveals about Big Pharma's playbook

AbbVie's success in navigating Humira's decline holds lessons for pharmaceutical companies, investors and policymakers.

Full story

#1

Physicians are in short supply. They are costly. Is the APP the answer to the CMO's workforce and budget challenges? ...

Amid the hype and promise, a growing tension is becoming clear: the reality of what AI can deliver versus what it can't. ...